Cyprotex PLC Executive Option Scheme (5105M)
January 21 2016 - 2:00AM
UK Regulatory
TIDMCRX
RNS Number : 5105M
Cyprotex PLC
21 January 2016
21 January 2016
Cyprotex PLC
("Cyprotex" or the "Company" or the "Group")
Executive Option Scheme
Anthony Baxter and John Dootson ("the Executives") were granted
share options on 28(th) January 2014 in respect of 2,000,000
ordinary shares of 1p each and 16(th) April 2014 in respect of
333,333 ordinary shares of 1p each respectively ("the
Options").
To further align the Executives interests with those of the
shareholders, the Company announces today that the Executives will
not receive discretionary performance related bonuses in respect of
the trading year ended 31 December 2015 thereby preserving cash
within the Company, however, the performance condition relating to
a minimum share price of 120 pence upon change of control of the
Company has been removed from the Options.
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20
Cyprotex) 7496 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors:
Cyprotex PLC
Cyprotex islisted on the AIM market of the London Stock Exchange
(CRX). It has sites at Macclesfield and Alderley Park, both of
which are near Manchester in the UK, and at Watertown, MA and
Kalamazoo, MI in the US. The Company was established in 1999 and
works with more than 1300 partners within the pharmaceutical and
biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. In 2015, Cyprotex launched its new bioscience division
to expand its capabilities into phenotypic and target based
screening. The Company's core capabilities include high quality in
vitro ADME screening services, mechanistic toxicology and high
content toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, bioscience services,
predictive modelling using PBPK, including Cloe(R) PK for in vivo
PK prediction, and a range of skin, ocular and endocrine disruption
services. For more information, see www.cyprotex.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDBLFLQFFZBBE
(END) Dow Jones Newswires
January 21, 2016 02:00 ET (07:00 GMT)
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024
